Phase II clinical trial of VX-497 for HCV infection begins.
D000998:Antiviral Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors*
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D007168:IMP Dehydrogenase